Valneva SE (XPAR:VLA)

€ 3.872 0.062 (1.63%) Market Cap: 538.80 Mil Enterprise Value: 573.83 Mil PE Ratio: 0 PB Ratio: 2.85 GF Score: 64/100

Q1 2024 Valneva SE Earnings Call Transcript
May 07, 2024

€3.42 (-0.06%)

Earnings
Full Year 2023 Valneva SE Earnings Call Transcript
Mar 20, 2024

€3.32 (-11.90%)

Earnings
Valneva SE Analyst Call Transcript
Nov 13, 2023
Q3 2023 Valneva SE Earnings Call Transcript
Nov 09, 2023

€6.31 (+4.33%)

Earnings
Half Year 2023 Valneva SE Earnings Call Transcript
Sep 21, 2023

€6 (-3.10%)

Earnings
Valneva SE at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Valneva SE Earnings Call Transcript
May 04, 2023

€5.24 (+24.45%)

Earnings
Full Year 2022 Valneva SE Earnings Call Transcript
Mar 23, 2023

€4.8 (-1.07%)

Earnings
Valneva SE Corporate Analyst Meeting Transcript
Dec 06, 2022
Q3 2022 Valneva SE Earnings Call Transcript
Nov 10, 2022

€6.99 (+5.17%)

Earnings
Half Year 2022 Valneva SE Earnings Call Transcript
Aug 11, 2022

€10.01 (-1.52%)

Earnings
Valneva SE at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Valneva SE COVID-19 Vaccine Purchase Agreement Update Transcript
May 16, 2022
Q1 2022 Valneva SE Earnings Call Transcript
May 05, 2022

€11.85 (-0.21%)

Earnings
Full Year 2021 Valneva SE Earnings Call Transcript
Mar 24, 2022

€17.31 (+0.87%)

Earnings
Valneva SE - Special Call Transcript
Oct 18, 2021
Half Year 2021 Valneva SE Earnings Call Transcript
Aug 10, 2021

€10.91 (-13.69%)

Earnings
Valneva SE Annual Shareholders Meeting Transcript
Jun 23, 2021
Q1 2021 Valneva SE Earnings Call Transcript
May 20, 2021

€12.06 (-3.37%)

Earnings
Full Year 2020 Valneva SE Earnings Call Transcript
Feb 25, 2021

€11.26 (+0.36%)

Earnings
Q3 2020 Valneva SE Earnings Call Transcript
Nov 03, 2020

€5.66 (-13.46%)

Earnings
Half Year 2020 Valneva SE Earnings Call Transcript
Aug 04, 2020

€5.05 (-5.61%)

Earnings
Q1 2020 Valneva SE Earnings Call Transcript
May 07, 2020

€3.8 (-2.56%)

Earnings
Full Year 2019 Valneva SE Earnings Call Transcript
Feb 27, 2020

€2.96 (-4.82%)

Earnings
Nine Months 2019 Valneva SE Earnings Call Transcript
Oct 31, 2019

€2.51 (-5.64%)

Earnings
Half Year 2019 Valneva SE Earnings Call Transcript
Aug 01, 2019

€3.09 (+0.65%)

Earnings
Valneva SE R&D Investor Day Presentation Transcript
Jul 09, 2019
Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call Transcript
Jun 21, 2019
Q1 2019 Valneva SE Earnings Call Transcript
May 02, 2019

€3.43 (+4.26%)

Earnings
Full Year 2018 Valneva SE Earnings Call Transcript
Feb 21, 2019

€3.15

Earnings

Valneva SE Analyst Call Transcript

Nov 13, 2023 / 02:00PM GMT

Release Date Price: €6.27 (-1.38%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to Valneva Announces U.S. FDA approval of World's First Chikungunya Vaccine, IXCHIQ. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Josh Drumm, VP, Global Investor Relations. Please go ahead.

Joshua Drumm

Valneva SE - VP of IR

Thank you, Nadia. Hello, and thank you for joining us. We're excited to discuss the recent FDA approval of IXCHIQ, the world's first chikungunya vaccine and the third vaccine the company has advanced from early development to commercialization. It's my pleasure to welcome you today. Please note that you can find our press release from Friday and the analyst presentation published earlier today available within the Investors section of our website.

I'm joined today by Valneva's CEO, Thomas Lingelbach; and Chief Medical Officer -- Chief Medical Officer, Juan Carlos Jaramillo, who will provide an overview of chikungunya and IXCHIQ, the market outlook and the ongoing planned

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.